QDEL - Quidel more quick diagnosis Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : QDEL - Quidel more quick diagnosis

QDEL 28.14

+5.8%

3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Robert Busse who wrote (439)	2/24/1997 6:58:00 PM
From: Mike Relyea	of 1693

Bob, Glaxo wouldn't be spending the big bucks need for a Phase III trial if it didn't think GG167 had a high probability (my guess: above 80 percent) of getting FDA approval. We should get an announcement by Glaxo soon, and I wouldn't be surprised if Quidel provides an update on its progress in developing a flu test. This should insure continued funding by Glaxo for the development of Quidel's flu test. World-wide filing for zanamivir, GG167, is planned to take place in the second half of 1998. That's only one a year from now. Speculation on the successful outcome for the test and treatment should have a positive effect on Quidel's stock, since with more than 350 million cases of influenza around the world each year, there's no doubt a Quidel test and Glaxo treatment will be huge sellers. biz.yahoo.com Mike

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next